BACKGROUND: It is unclear whether benefits outweigh harms for routine screening and prophylactic revascularization to prevent coronary artery disease (CAD) in asymptomatic kidney transplant candidates. STUDY DESIGN: Pilot feasibility study with prospective observational data collection and patient interviews. SETTING & PARTICIPANTS: Consecutive patients referred for kidney and/or pancreas transplant at 26 major transplant centers in the United States. PREDICTORS: Older age, diabetes, prior cardiovascular disease, and multiple traditional CAD risk factors. OUTCOMES: Eligibility and willingness to participate in a randomized controlled trial (RCT) to study the effect of CAD screening on major adverse cardiac events. MEASUREMENTS: Patients who would be candidates for a hypothetical RCT of CAD screening were interviewed and asked if they would participate in such a trial. Sample size for the trial was estimated using data for Medicare patients in the US Renal Data System with major adverse cardiac events as the primary end point. RESULTS: Of consecutive eligible patients, CAD evaluation was not indicated in 398 (24%), already completed before referral in 602 (36%), and pending (and hence eligible for an RCT) in 665 (40%). Of 241 interviewed, 73% indicated they would be willing to participate in an RCT. We estimated that ~4,000 would need to be enrolled to detect a 20% decrease in major adverse cardiac events at >80% power at P < 0.05. LIMITATIONS: Willingness to participate in an actual clinical trial may be different from indicated in an interview. CONCLUSION: An RCT to compare the effects of routine screening for CAD versus no screening on major adverse cardiac events is feasible.
RCT Entities:
BACKGROUND: It is unclear whether benefits outweigh harms for routine screening and prophylactic revascularization to prevent coronary artery disease (CAD) in asymptomatic kidney transplant candidates. STUDY DESIGN: Pilot feasibility study with prospective observational data collection and patient interviews. SETTING & PARTICIPANTS: Consecutive patients referred for kidney and/or pancreas transplant at 26 major transplant centers in the United States. PREDICTORS: Older age, diabetes, prior cardiovascular disease, and multiple traditional CAD risk factors. OUTCOMES: Eligibility and willingness to participate in a randomized controlled trial (RCT) to study the effect of CAD screening on major adverse cardiac events. MEASUREMENTS: Patients who would be candidates for a hypothetical RCT of CAD screening were interviewed and asked if they would participate in such a trial. Sample size for the trial was estimated using data for Medicare patients in the US Renal Data System with major adverse cardiac events as the primary end point. RESULTS: Of consecutive eligible patients, CAD evaluation was not indicated in 398 (24%), already completed before referral in 602 (36%), and pending (and hence eligible for an RCT) in 665 (40%). Of 241 interviewed, 73% indicated they would be willing to participate in an RCT. We estimated that ~4,000 would need to be enrolled to detect a 20% decrease in major adverse cardiac events at >80% power at P < 0.05. LIMITATIONS: Willingness to participate in an actual clinical trial may be different from indicated in an interview. CONCLUSION: An RCT to compare the effects of routine screening for CAD versus no screening on major adverse cardiac events is feasible.
Authors: Don Poldermans; Jeroen J Bax; Olaf Schouten; Aleksandar N Neskovic; Bernard Paelinck; Guido Rocci; Laura van Dortmont; Anai E S Durazzo; Louis L M van de Ven; Marc R H M van Sambeek; Miklos D Kertai; Eric Boersma Journal: J Am Coll Cardiol Date: 2006-08-17 Impact factor: 24.094
Authors: Edward O McFalls; Herbert B Ward; Thomas E Moritz; Steven Goldman; William C Krupski; Fred Littooy; Gordon Pierpont; Steve Santilli; Joseph Rapp; Brack Hattler; Kendrick Shunk; Connie Jaenicke; Lizy Thottapurathu; Nancy Ellis; Domenic J Reda; William G Henderson Journal: N Engl J Med Date: 2004-12-30 Impact factor: 91.245
Authors: Gabriel M Danovitch; Sundaram Hariharan; John D Pirsch; David Rush; David Roth; Emilio Ramos; Randall C Starling; Chuck Cangro; Mattthew R Weir Journal: J Am Soc Nephrol Date: 2002-02 Impact factor: 10.121
Authors: Ravinder K Wali; Gregory S Wang; Stephen S Gottlieb; Lavanya Bellumkonda; Riple Hansalia; Emilio Ramos; Cinthia Drachenberg; John Papadimitriou; Meredith A Brisco; Steve Blahut; Jeffrey C Fink; Michael L Fisher; Stephen T Bartlett; Matthew R Weir Journal: J Am Coll Cardiol Date: 2005-04-05 Impact factor: 24.094
Authors: E L Ramos; B L Kasiske; S R Alexander; G M Danovitch; W E Harmon; L Kahana; T J Kiresuk; J F Neylan Journal: Transplantation Date: 1994-02-27 Impact factor: 4.939
Authors: Hallvard Holdaas; Bengt Fellström; Alan G Jardine; Ingar Holme; Gudrun Nyberg; Per Fauchald; Carola Grönhagen-Riska; Søren Madsen; Hans-Hellmut Neumayer; Edward Cole; Bart Maes; Patrice Ambühl; Anders G Olsson; Anders Hartmann; Dag O Solbu; Terje R Pedersen Journal: Lancet Date: 2003-06-14 Impact factor: 79.321
Authors: Andrew G Bostom; Myra A Carpenter; Lawrence Hunsicker; Paul F Jacques; John W Kusek; Andrew S Levey; Joyce L McKenney; Renee Y Mercier; Marc A Pfeffer; Jacob Selhub Journal: Am J Kidney Dis Date: 2008-11-20 Impact factor: 8.860
Authors: D E Weiner; M A Carpenter; A S Levey; A Ivanova; E H Cole; L Hunsicker; B L Kasiske; S J Kim; J W Kusek; A G Bostom Journal: Am J Transplant Date: 2012-05-17 Impact factor: 8.086
Authors: Ailish Nimmo; Nicholas Latimer; Gabriel C Oniscu; Rommel Ravanan; Dominic M Taylor; James Fotheringham Journal: Transpl Int Date: 2022-06-27 Impact factor: 3.842